A2B Adenosine Receptor as a novel target in cancer immunotherapyvalidation and optimization of new ligands
- Eddy Sotelo Pérez Director
Universidade de defensa: Universidade de Santiago de Compostela
Fecha de defensa: 06 de outubro de 2023
- Santiago Vázquez Cruz Presidente/a
- Julio César Castro Palomino Laria Secretario/a
- María Laura Bolognesi Vogal
Tipo: Tese
Resumo
This doctoral thesis focuses on the study of purinergic signaling in cancer, specifically targeting adenosine receptors. The main objective is the development of potent and selective nonxanthine- based antagonists for adenosine A2B receptors, with potential applications in cancer-targeted therapies. Molecular design strategies, synthesis, biological evaluation, structureactivity relationships, enantiospecific recognition and molecular modeling are explored. To the end, a rational method for dual A2A/A2B antagonists were obtained. The optimization and preclinical validation of new ligands for cancer (immuno)therapy are investigated, revealing promising data in terms of pharmacokinetics and pharmacodynamics.